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was normalized by day 7. Patency was 100% and survival was
diminished by 50% in these large AVFs. Shear stress in AVFs
created with the 28-gauge needle was decreased by 39% but
AVF patency was reduced 50%. Survival was 100%.
Conclusions: This murine aortocaval model faithfully
recapitulates the maturation and failure phases of the human
AVF; this is the ﬁrst animal model to show these distinct
phases. Shear stress varies according to the diameter of the
ﬁstula. and AVF patency depends on the AVF shear stress.
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Objectives: Contrast-induced nephropathy (CIN) is the
third leading cause of hospital-acquired renal failure. Early
diagnosis and treatment of CIN may prevent signiﬁcant
sequelae. It has been reported that urinary ﬁbrinogen (Fg)
can be used as a biomarker of ischemia-reperfusion injury in
kidney. The objective of this study was to investigate whether
urinary Fg can serve as a biomarker for the diagnosis of CIN.
Methods: C57B1/6J mice received a prostaglandin
synthesis inhibitor (indomethacin, 10 mg/kg) and a nitric
oxide synthase inhibitor (Nu-Nitro-L-arginine methyl ester,
10 mg/kg) intraperitoneally (i.p.), before being given iodix-
anol in low-dose (6.24 g iodine/mL i.p.) and high-dose
(12.48 g iodine/kg i.p.) groups. Mice in the control group
received normal saline instead of iodixanol. Urine samples
were collected for Fg and creatinine (Cr) analysis using an
enzyme-linked immunosorbent assay kit. Kidneys were har-
vested 24 hours later. RNA was extracted from half of a kid-
ney specimen. Quantitative RT-PCR was used to quantify
Fg-a RNA expression, with glyceraldehyde-3-phosphate de-
hydrogenase as the endogenous control. The other half of
the kidney specimen was ﬁxed with formalin, embedded in
parafﬁn, and then stained with hematoxylin and eosin
(H&E) for histopathologic evaluation.
Results: H&E stain demonstrated mild renal injury in
the low-dose group, scoring from 0 to 1, and moderate
renal injury in high-dose group scoring from 1 to 2, based
on a pathologic grading scale of 0 to 3. Urinary Fg
increased signiﬁcantly from 0.37 6 0.13 mg/mg Cr in
the control group to 3.46 6 2.89 mg/mg Cr in the
low-dose group (P < .05) and 6.15 6 2.51 mg/mg Cr
in the high-dose group (P < .01). Fg-a RNA level
increased 40% in high-dose group compared with the con-
trol (P < .05), although no signiﬁcant changes were
detected in the low-dose group.Conclusions: Urinary Fg level increases are consistent
with the pathologic severity of CIN in animal models.
These results suggest that urinary Fg may be a potential
biomarker for early diagnosis of CIN. Further investigation
in clinical patients is needed.
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Objectives: Free radicals have been implicated in myo-
nephropathic metabolic syndrome (MNMS), which dam-
ages not only muscles but also kidneys. At Vascular
Annual Meeting (VAM) 2012, we reported the free radical
scavenger, edaravone (Radicut, Mitsubishi Tanabe Pharma
Co, Japan), suppresses muscle injury by MNMS. In this
study, we evaluated whether edaravone can suppress kidney
damage by MNMS.
Methods: Lewis male rats (508 6 31 g, n ¼ 10)
were intraperitoneally injected with 3.0 mg/kg of edar-
avone (edaravone group [n ¼ 4]), or saline (MNMS
group [n ¼ 6]). The MNMS models were induced by
clamping the bilateral common femoral arteries for 5
hours and then declamping. Five hours after declamping,
the both kidneys were stained with hematoxylin and
eosin (Fig). Normal kidneys were harvested as a control
(n ¼ 3). Kidney damage was evaluated by the number of
cells in the glomerulus (glomerulus inﬁltration) and by
the number of residual tubular cells (enlargement of
tubular cells).
Results: The number of cells in the glomerulus was
signiﬁcantly increased in the MNMS group compared
with the control (77.2 6 10.3 vs 49.6 6 2.8 cells/
glomerulus, P < .01). The number of cells in the
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10.3 cells/glomerulus; P < .01). The number of residual
tubular cells was signiﬁcantly decreased in the MNMS
group compared with the control (555 6 24 vs 957 6
44 cells/mm2; P < .001). The number of residual tubular
cells was maintained in the edaravone group (654 6 38
cells/mm2; P ¼ .06).
Conclusions: MNMS was associated with signiﬁcant
glomerular inﬁltration and the enlargement of tubular
cells. Edaravone may alleviate kidney damages caused by
MNMS.
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Objectives: Recent literature suggests that platelet
function supports vessel integrity. Toll-like receptor 2
(TLR2) has been shown to be present and functionally
active on platelets. We have previously demonstrated that
TLR2 knockout (KO) mice hemorrhage into ischemic hin-
dlimbs. We hypothesize that TLR2 function is required to
maintain angiogenic vessel integrity, possibly by promoting
normal platelet function.
Methods: Blood from C57BL/6 (control) and
TLR2-KO mice was obtained by cardiac puncture. In
some experiments, control C57BL/6 mice were treated
with anti-TLR2 antibody and control immunoglobulin
G. Platelets were separated and washed, and treated with
1 U/mL thrombin, 50 ng/mL phorbol-myristate acetate
(PMA), 100mM calcium ionophore A23187, and 30mM
thrombin receptor-activating peptide (TRAP6). Fixed
platelets were stained with ﬂuorescent antibodies to b-3
of the glycoprotein (GP)IIb/IIIa complex, and P-selectin,Fig. TLR2KOmice demonstrate less platelet P-selectin expression
compared to control in response to thrombin.a platelet-activation marker. Activation was assessed using
ﬂow cytometry.
Results: Platelets from TLR2KO mice had less
P-selectin expression in response to thrombin than con-
trols (P ¼ .036; Fig). However, compared with con-
trols, activation with TRAP6 and calcium ionophore
resulted in higher P-selectin expression in both
TLR2KO mice (P ¼ .056) and TLR2 antibody-treated
mice (P ¼ .0009).
Conclusions: These data indicate that innate immune
receptors on platelets modulate activation in a context-
speciﬁc manner. Further research is necessary to delineate
the role of platelet-mediated innate immune responses in
angiogenesis after ischemia.
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Objectives: To quantify and evaluate the complica-
tions arising from indwelling inferior vena cava (IVC) ﬁlters
through the examination of incidentally performed
computed tomography (CT) scans.
Methods: A retrospective review was conducted of all
patients who had an IVC ﬁlter placed at our institution
from January 1, 2000, to December 31, 2011. All patients
who had incidental CT studies in which the IVC ﬁlter was
visible and which were performed at least 6 months after
placement were included. Two observers independently
evaluated the CT scans. Filter model as well as IVC penetra-
tion, erosion, migration, ﬁlter fracture, and other complica-
tions were recorded. Penetration of the IVC was deﬁned by
at least one strut of the device being >4 mm outside of the
IVC wall.
Results: A total of 1470 ﬁlters of eight different models
were inserted in the speciﬁed time period. Of these, 66%
were retrievable, 6.9% were removed, and 0.8% failed
removal. The number of these patients who had had inci-
dental CT studies performed in which the IVC ﬁlters were
visible was 335 (22.7%, n 1-60; range, 1 month-10 years).
Filter penetration of the IVC was observed in 129 (38.5%)
of the ﬁlters seen on subsequent CT scans, which further cal-
culates to a known overall perforation rate of 9% for the entire
series. IVCpenetrationwas observed in 42 of 163Optease ﬁl-
ters (26%),41of107Trapeaseﬁlters (38%),25of29G2/G2X
ﬁlters (86%), 9of14Greenﬁeldﬁlters (64%), 1of9Vena-Tech
ﬁlters (11%), 6 of 8 Celect ﬁlters (75%), 3 of 3 Eclipse ﬁlters,
(100%), and 2 of 2 Tulip ﬁlters (100%).
Conclusions: IVC ﬁlters were found to have a high
rate of IVC penetration when observed through incidental
CT scans. Further prospective studies and programs are
needed to increase IVC ﬁlter retrieval rate.
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